Sanofi SA

1SAN

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,828.702.300.03%
CAC 407,766.7143.240.56%
DAX 4024,206.91133.240.55%
Dow JONES (US)44,240.76165.60-0.37%
FTSE 1008,854.1847.650.54%
HKSE24,148.07260.241.09%
NASDAQ20,418.465.950.03%
Nikkei 22539,688.81101.130.26%
NZX 50 Index12,839.6919.33-0.15%
S&P 5006,225.524.46-0.07%
S&P/ASX 2008,590.701.400.02%
SSE Composite Index3,497.4824.350.70%

Market Movers